Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToPCourT: Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in TNBC
NCT06027268Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib and pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Objective Response at 6 months. Started Jan 2024; status: active, not recruiting.
02
Drugs
trilaciclibpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06027268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027268.